To determine the molecular defect accounting for the deficiency of pulmonary surfactant protein B (SP-B) in full-term neonates who died from respiratory failure associated with alveolar proteinosis, the sequence of the SP-B transcript in affected infants was ascertained. A frameshift mutation consisting of a substitution of GAA for C in codon 121 of the SP-B cDNA was identified. The three affected infants in the index family were homozygous for this mutation, which segregated in a fashion consistent with autosomal recessive inheritance of disease. The same mutation was found in two other unrelated infants who died from alveolar proteinosis, one of whom was also homozygous, and in the parents of an additional unrelated, affected infant, but was not observed in 50 control subjects. We conclude that this mutation is responsible for SP-B deficiency and neonatal alveolar proteinosis in multiple families and speculate that the disorder is more common than was recognized previously. (J.
Introduction
A developmentally determined lack of pulmonary surfactant, the mixture oflipids and specific proteins that reduces alveolar surface tension, is recognized as the principal cause ofthe respiratory distress syndrome in infants born prematurely (1) . A deficiency of surfactant protein B (SP-B), ' an 8,000-D lungspecific protein, was recently demonstrated in three full-term siblings who died from respiratory failure associated with histopathologic changes of alveolar proteinosis (2) . SP-B has an important role in the surface tension-lowering properties of pulmonary surfactant, and congenital alveolar proteinosis (CAP) is a recognized familial cause offatal respiratory disease in full-term infants (3) (4) (5) (6) . These observations suggest that an inherited deficiency of SP-B may cause this disorder and that abnormalities of surfactant proteins due to genetic mechanisms could cause respiratory disease. To test these hypotheses and to elucidate the molecular mechanisms responsible for the lack of SP-B in these infants, we analyzed the SP-B transcripts in infants with CAP from unrelated families and compared them with previously published SP-B cDNA and genomic sequences (7) (8) (9) (10) .
Methods
Patients. The clinical course of infants from the index family (patients 11. 1, II.5, and II.6) and patient CAP-2 has been described previously (2, 6) . Patient CAP-3 was a 3-kg Caucasian female who developed respiratory distress shortly after birth and who subsequently required intubation, mechanical ventilation, and extracorporeal membrane oxygenation. Open lung biopsy at 2 mo of age demonstrated characteristic findings of alveolar proteinosis: distal airspaces were filled with granular, eosinophilic material that stained positively with periodic acidSchiff reagent, with foamy macrophages suspended in the proteinaceous material. She died at age 3 mo from respiratory failure; findings of alveolar proteinosis were also present at autopsy. Lung tissue from patients CAP-2 and CAP-3 was analyzed for SP-B content by immunohistochemical staining and protein blotting as described previously (2) . Control blood samples were obtained from healthy adult volunteers without symptoms of pulmonary disease.
cDNA preparation and sequencing. Genomic DNA preparation and restriction analysis. Genomic DNA was prepared from whole blood lymphocytes (patients 1.1, I.2, 11.2, II.3, 11.4, and controls), frozen lung tissue (patients II.5, II.6, CAP-2, and CAP-3), or formalin-fixed paraffin-embedded lung tissue (patient II. 1) as described previously (13, 14) . 200 ng of genomic DNA was used in the PCR. After denaturation at 950C for 5 min, 35 cycles of denaturation at 950C for 30 s, annealing at 590C for 30 s, and extension at 720C for 45 s were performed using a thermal cycler (National Labnet Co., Woodbridge, NJ) followed by a 10-min incubation at 720C. The primers used were 5'-GGC CTT GTG TCC AGG GAC-3' in the sense orientation and 5'-TGT GTG TGA GAG TGA GGG TGT AAG-3' in the antisense orientation ( 15) , corresponding to positions 1383-1400 and 2135-2158, respectively, of the SP-B gene sequence (7) , which are predicted to amplify a 776-bp DNA fragment. After amplification, a l6-,d aliquot ofthe PCR reaction was digested with 15 U of SfuI (Boehringer Mannheim Corp., Indianapolis, IN) using reagents and conditions supplied by the manufacturer. The resulting products were separated on a 2.0% agarose gel and visualized by ethidium bromide staining.
Results SP-B cDNA was detectable by RT-PCR in the lung tissue ofthe index patient with SP-B deficiency and alveolar proteinosis, although the amount of SP-B-deficient cDNA was markedly less than that generated by RT-PCR from RNA obtained from control lung tissue (not shown). Sequence analysis of the SP-B-deficient cDNA clones revealed a substitution ofthree bases (GAA) for the single nucleotide (C) at position 375 ofthe SP-B cDNA, disrupting codon 121 ( Fig. 1 ) (referred to as 121 ins2). This sequence was found in all cDNAs generated from each set ofprimer pairs that spanned this region. Direct sequence analysis of genomic DNA from this infant and an affected sibling (patient 11.6) confirmed this sequence. The net gain of two bases causes a frameshift, introducing a premature signal for termination of translation after codon 214.
Analysis of SP-B-deficient cDNA clones from both the index patient and an affected sibling (patient II.6) for the sequence distal to the 121 ins2 mutation indicated the presence of two transcripts, present in approximately equal amounts as determined from multiple PCR reactions. In one of these transcripts exon 7 was deleted, and in a second transcript exon 7 was present, but a cryptic splice site 12 bp 3' of the reported exon 8 splice junction was used (Fig. 2) (Fig. 3) . The patterns after SfuI _ To ascertain whether the 121 ins2 mutation was unique to this family, the presence of this mutation was looked for in the DNA of two other unrelated, full-term infants who died from respiratory failure associated with alveolar proteinosis and absent SP-B protein in their lung tissue. Restriction analysis demonstrated that one ofthese two infants was homozygous for the 121 ins2 mutation, and the other had the 121 ins2 mutation on only one allele, suggesting that she was a compound heterozygote for two different SP-B gene defects (Fig. 4) . Additionally, the parents of another infant with CAP (5), from whom tissue was not available, were both found to carry this mutation on one allele (not shown), implying that their affected child was homozygous. In contrast, restriction analysis ofPCR-amplified genomic DNA obtained from 50 unrelated adult controls without evidence of lung disease did not show the presence of this restriction site on any ofthe 100 chromosomes analyzed. In 11 ofthe control patients, two bands ofequal intensity were generated by PCR (not shown). This region of the SP-B gene is known to be polymorphic, containing dinucleotide repeats of variable length ( 15).
Discussion
CAP is a uniformly fatal lung disease characterized clinically by respiratory failure in the neonatal period and histopathologically by the accumulation of granular, eosinophilic, periodic acid-Schiff reagent-positive staining material in the distal airspaces. The recent observation that three siblings with this disorder lacked SP-B protein suggested that an inherited deficiency of SP-B was the cause of this disease. However, abnormalities of other surfactant components, including increased immunostaining for SP-C, an altered distribution of SP-A staining, and a markedly abnormal amniotic fluid phospholipid profile, were also observed in the SP-B-deficient infants (2, 16). Additionally, it was unknown if those observations applied to infants with CAP from other families. In this report, we demonstrate a recurrent mutation in the SP-B gene accounting for the lack of SP-B protein in multiple kindreds, establishing the lack of SP-B as the primary basis for disease in these families and SP-B deficiency as a common cause of CAP. Whether inherited abnormalities of other surfactant proteins produce similar disease is unknown. While the mechanism(s) whereby SP-B deficiency leads to the histopathological appearance of alveolar proteinosis remains unclear, these findings imply a role for SP-B in the metabolism of SP-A, SP-C, and surfactant phospholipids.
The frameshift and consequent premature termination codon clearly account for the lack of the 8,000-D SP-B protein, which is derived from codons 201 to 279 of the 381-amino acid proprotein, and likely account for the marked reduction in SP-B mRNA. The introduction of nonsense codons has been associated with a marked reduction in transcript level from the mutant allele of other genes including f3-globin ( 17 ) , aI-antitrypsin deficiency ( 18) , cystic fibrosis transmembrane regulator (19) , fibrillin (20) , and the insulin receptor (21) . The mechanism(s) leading to reduction in mRNA may be related to alterations in RNA processing (22) (23) (24) . The mechanisms and significance of the abnormalities in SP-B RNA splicing observed in the index patients (Fig. 2) are unclear. Both alterations are distal to the premature termination codon, which is in exon 6, and are thus unlikely to be causally related to the deficiency of SP-B protein. Abnormalities of RNA splicing have been observed in mutant alleles of other genes containing premature termination codons (20, 25) . Alternatively, these splicing abnormalities may also occur in normal tissue and were selected because of the marked reduction in normal SP-B transcript levels.
The incidence of SP-B deficiency associated with alveolar proteinosis is unknown. Affected infants also have features of respiratory distress syndrome, persistent pulmonary hypertension, and bronchopulmonary dysplasia and may not be recognized without autopsy or biopsy data or until a second child in the same family is affected (2, 6) . It is therefore likely that the syndrome has been underreported. Finding the identical mutation on seven of eight chromosomes from unrelated infants raises the possibility that the disease may be more common than has been appreciated and indicates that molecular techniques will be useful in diagnostic testing. Whether the presence of the same mutation in unrelated individuals is because ofa mutation arising in a common ancestor or reflects a mechanism causing a recurrent de novo mutation at this site is unknown. The finding of an apparent compound heterozygote SP-B-deficient patient suggests there is some molecular heterogeneity of this disorder.
At the present time there is no effective treatment for neonatal alveolar proteinosis, and gene therapy may be required to treat this disorder. Gene therapy trials for SP-B deficiency, which has a rapidly progressive course, may be helpful in developing strategies for treatment of other genetic illnesses such as cystic fibrosis and a1-antitrypsin deficiency which lead to more gradually progressive pulmonary disease.
